A novel strategy for targeting photodynamic therapy. Molecular combo of photodynamic agent zinc(II) phthalocyanine and small molecule target-based anticancer drug erlotinib

Chem Commun (Camb). 2013 Oct 25;49(83):9570-2. doi: 10.1039/c3cc45487h.

Abstract

In this study, two phthalocyanine-erlotinib conjugates linked by an oligoethylene glycol chain have been synthesised and fully characterised. Having erlotinib as the targeting moiety, the two conjugates exhibited high specific affinity to HepG2 cancer cells and tumour tissues, therefore leading to high photodynamic activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Drug Delivery Systems
  • Erlotinib Hydrochloride
  • Ethylene Glycol / chemistry
  • Hep G2 Cells
  • Humans
  • Indoles / administration & dosage*
  • Indoles / chemistry
  • Indoles / pharmacology
  • Isoindoles
  • Neoplasms / drug therapy
  • Organometallic Compounds / administration & dosage*
  • Organometallic Compounds / chemistry
  • Organometallic Compounds / pharmacology
  • Photochemotherapy
  • Photosensitizing Agents / administration & dosage*
  • Photosensitizing Agents / chemistry
  • Photosensitizing Agents / pharmacology
  • Quinazolines / administration & dosage*
  • Quinazolines / chemistry
  • Quinazolines / pharmacology
  • Zinc Compounds

Substances

  • Antineoplastic Agents
  • Indoles
  • Isoindoles
  • Organometallic Compounds
  • Photosensitizing Agents
  • Quinazolines
  • Zinc Compounds
  • Zn(II)-phthalocyanine
  • Erlotinib Hydrochloride
  • Ethylene Glycol